Do Alex Wu’s Form 3 entries reflect recent CASI share purchases or sales?

The Form 3 entries are coded as holdings, not new purchases or sales, and transaction codes are listed as unknown. The filing establishes Wu’s existing ownership position, rather than reporting new open-market trades or option exercises on the reported date.

CASI director Alex Wu reports option holdings

Accepted by SEC EDGAR 03/25/2026 - 07:36 AM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. director Alex Wu filed an initial ownership report showing equity interests in the company. The filing lists several fully vested stock options to buy Ordinary Shares, including grants covering 11,045, 38,838 and 11,753 underlying shares at an exercise price of $1.93 per share, plus additional options at $2.67, $3.59 and $1.26 per share. Wu also reports direct ownership of 34,168 Ordinary Shares. A footnote states that all of the reported options are fully vested and exercisable as of the date of this form, meaning they can be converted into Ordinary Shares at the stated exercise prices through their respective expiration dates in 2031 through 2035.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Wu Alex

Role Director

Type	Security	Shares	Price	Value
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Ordinary Share	--	--	--

Holdings: Option (right to buy) — 105,142 options (Direct); Ordinary Share — 34,168 shares (Direct)

Footnotes (1)

F1. The options are fully vested and exercisable as of the date of this form.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Alex Wu’s Form 3 filing show for CASI (CASIF)?

Alex Wu’s Form 3 shows his initial ownership in CASI Pharmaceuticals, including multiple fully vested stock options and 34,168 directly held Ordinary Shares. The options give him the right to buy shares at fixed exercise prices through expirations between 2031 and 2035.

How many CASI Ordinary Shares does Alex Wu hold directly?

Alex Wu reports direct ownership of 34,168 CASI Ordinary Shares. This figure reflects his existing share position separate from options, which provide rights to acquire additional Ordinary Shares at specified exercise prices if he chooses to exercise them in the future.

What stock options does Alex Wu report in his CASI Form 3?

Alex Wu reports several options to buy CASI Ordinary Shares, including tranches over 11,045, 38,838 and 11,753 underlying shares at an exercise price of $1.93. Additional option grants carry exercise prices of $2.67, $3.59 and $1.26 per share with later expiration dates.

Are Alex Wu’s CASI stock options vested and exercisable?

Yes. A footnote states the options are fully vested and exercisable as of the Form 3 date. This means Wu can choose to exercise these options at their stated exercise prices any time before they expire between 2031 and 2035, subject to plan terms.

What are the expiration dates of Alex Wu’s CASI stock options?

The reported CASI stock options held by Alex Wu expire on various dates from June 15, 2031 through July 21, 2035. Each option grant retains its own expiration date, after which any unexercised right to buy CASI Ordinary Shares would lapse.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wu Alex

(Last)

(First)

(Middle)

601 GATEWAY BLVD, SUITE 1250

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Share	34,168	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option (right to buy)	⁽¹⁾	06/15/2031	Ordinary Share	11,045	$1.93	D
Option (right to buy)	⁽¹⁾	05/25/2032	Ordinary Share	38,838	$1.93	D
Option (right to buy)	⁽¹⁾	04/14/2033	Ordinary Share	11,753	$1.93	D
Option (right to buy)	⁽¹⁾	06/18/2034	Ordinary Share	11,753	$2.67	D
Option (right to buy)	⁽¹⁾	06/26/2034	Ordinary Share	20,000	$3.59	D
Option (right to buy)	⁽¹⁾	07/21/2035	Ordinary Share	11,753	$1.26	D

Explanation of Responses:

1. The options are fully vested and exercisable as of the date of this form.

	/s/ Alex Wu	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR